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A B S T R A C T
GLI1 is one of three transcription factors (GLI1, GLI2 and GLI3) that mediate the Hedgehog signal transduction
pathway and play important roles in normal development. GLI1 and GLI2 form a positive-feedback loop and
function as human oncogenes. The mouse and human GLI1 genes have untranslated 5′ exons and large introns 5′
of the translational start. Here we show that Sonic Hedgehog (SHH) stimulates occupancy in the introns by
H3K27ac, H3K4me3 and the histone reader protein BRD4. H3K27ac and H3K4me3 occupancy is not sig-
niﬁcantly changed by removing BRD4 from the human intron and transcription start site (TSS) region. We
identiﬁed six GLI binding sites (GBS) in the ﬁrst intron of the human GLI1 gene that are in regions of high
sequence conservation among mammals. GLI1 and GLI2 bind all of the GBS in vitro. Elimination of GBS1 and 4
attenuates transcriptional activation by GLI1. Elimination of GBS1, 2, and 4 attenuates transcriptional activation
by GLI2. Eliminating all sites essentially eliminates reporter gene activation. Further, GLI1 binds the histone
variant H2A.Z. These results suggest that GLI1 and GLI2 can regulate GLI1 expression through protein-protein
interactions involving complexes of transcription factors, histone variants, and reader proteins in the regulatory
intron of the GLI1 gene. GLI1 acting in trans on the GLI1 intron provides a mechanism for GLI1 positive feedback
and auto-regulation. Understanding the combinatorial protein landscape in this locus will be important to in-
terrupting the GLI positive feedback loop and providing new therapeutic approaches to cancers associated with
GLI1 overexpression.
1. Introduction
The Sonic Hedgehog/Patched/GLI pathway is important for normal
development, cancer and congenital anomalies [1–3]. It is a complex
signal transduction pathway involving reversal of negative regulation
of a seven span transmembrane protein, Smoothened (SMO) by the
receptor Patched (PTCH) following stimulation by the ligand Sonic
Hedgehog (SHH). SHH signaling is mediated by three transcription
factors, GLI1, GLI2 and GLI3. Without SHH ligand transcriptional ac-
tivity of these factors is repressed by Suppressor of Fused (SuFu). SuFu
binds the GLI factors preventing them from moving to the nucleus. SHH
signaling activity is located in the primary cilium of the cell where the
presence of SHH ligand causes PTCH to be endocytosed internalizing
the SHH/PTCH complex and preventing PTCH from sequestering SMO
intracellularly. PTCH then does not inhibit SMO, induces SMO to lo-
calize in the base of the primary cilium, and represses SuFu. SHH sig-
naling, through PTCH/SMO, recruits GLI/SuFu to the ciliary tip where
they are rapidly dissociated [4]. This promotes nuclear localization of
the GLI transcription factors allowing target gene regulation [5–7].
SuFu may also act as a chaperon to the GLI transcription factors, par-
ticipating in chromatin complexes and facilitating import and export of
GLI factors from the nucleus [8].
A signiﬁcant disease burden is associated with mis-regulation of this
signal transduction pathway [1]. Constitutive signaling activity is as-
sociated with cancers or birth defects while decreased signaling activity
is associated with birth defects. GLI1 is a human oncogene and
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constitutive activation, either as a result of canonical pathway activa-
tion or non-canonical activation, of GLI1 is associated with many
human cancers [9–11]. Clinical trials have been conducted to establish
the eﬃcacy of down-regulating the pathway in patients by interfering
with SMO [12,13]. Unfortunately this approach may not be eﬀective in
many patients because of non-canonical signaling, which directly acti-
vates GLI1 and bypasses the block at the level of SMO. Thus there is a
need to target GLI1 to more eﬀectively block the pathway and optimize
the chance for therapeutic eﬃcacy. In order to ameliorate the disease
burden associated with this gene pathway and thereby improve the
public health, we need to more fully understand how GLI1 regulates
transcription and what regulates GLI1 expression.
GLI1 is transcriptionally activated by GLI2, and non-canonical sig-
naling, independent of SHH, PTCH and SMO, has been observed
through several pathways (KRAS, TGFbeta, WNT) and with transcrip-
tion factors, including c-MYC and EWSR1-FLI1, that directly activate
transcription of GLI1 [14–18]. Importantly GLI1 expression feeds for-
ward inducing GLI1 expression [19]. Negative regulation of the feed-
back loop can be provided by GLI3, translational repression or by the
repressive eﬀects of the lncRNA, GLI1as (GLI1 antisense long non-
coding RNA) [20].
The interplay of chromatin landscape and transcription factors is
key to regulation of gene expression. It is well established that epige-
netic modiﬁcation of histones correlates with transcriptional activity. In
particular H3K27ac and H3K4me3 are present at sites of active tran-
scription [21]. Altered histones are believed to be “sensed” by a class of
proteins known collectively as reader proteins [22,23]. These include
bromodomain proteins that recognize acetylation marks on histones.
Their role in transcriptional regulation remains to be fully elucidated
but their ability to bind modiﬁed histones is suﬃciently important to
transcriptional regulation to motivate the development of small mole-
cule inhibitors to modulate activity in cancers [24]. A particularly
important bromodomain reader protein, BRD4, binds histone H3 and
H4 acetylated tails as well as histone methylases [25]. BRD4 is an im-
portant regulator of gene activity in several cancers [26–28].
Given the widespread association of GLI1 with many human cancers
including glioblastoma, basal cell carcinoma, lung cancer, GI cancers,
prostate cancer [1], medulloblastoma [11,29,30] and rhabdomyo-
sarcoma [31–33], it is important to understand key elements of the
regulation of GLI1 expression. Here we show that the intronic region 5′
of the GLI1 translational start is a regulatory region with chromatin
features of an enhancer. The ﬁrst intron in the human locus contains
numerous cis elements, and is associated with H3K27ac marks and
DNase hypersensitivity clusters. We show that SHH stimulates occu-
pancy in this region by H3K27ac, H3K4me3 and the reader protein
BRD4 and that BRD4 can be removed from the human intron and TSS
region without resulting in lower H3K27ac and H3K4me3 occupancy.
Our sequencing a number of years ago and public reference sequence
data show six conserved GLI binding sites (GBS) in the large ﬁrst intron
of the human GLI1 gene. We show that these six GBS in the ﬁrst intron
of the human GLI1 gene are in regions of high sequence conservation
among mammals. Elimination of GBS1 and 4 attenuates transcriptional
activation by GLI1. Elimination of GBS1, 2, and 4 attenuates tran-
scriptional activation by GLI2. Deletions of combinations of the GBS
indicate a hierarchy of importance of the sites. Eliminating all sites
eliminates target gene activation. GLI1 and GLI2 bind the sites and GLI1
binds the histone variant H2A.Z. The results suggest that GLI1 expres-
sion can be auto-regulated by the GLI genes GLI1 and GLI2 through
protein complex binding to this region of the GLI1 gene. Elucidating the
combinatorial protein-protein interactions that regulate GLI1 expres-
sion will provide new therapeutic approaches to GLI1 induced cancers
overcoming the shortfall of upstream inhibitors whose eﬃcacy is lim-
ited by non-canonical signaling.
2. Results
2.1. The ﬁrst intron of human GLI1 has the characteristics of an enhancer
and contains conserved putative GLI binding sites (GBS)
The ﬁrst exon of the human GLI1 gene is non-coding and the ATG
translational start is at the 5′ end of the second exon [34]. The ﬁrst
intron of the human GLI1 gene is highly conserved among mammals
(Fig. 1). The region has several DNase hypersensitivity clusters, in-
dicating open chromatin, and H3K27ac marks in multiple cell lines.
Transcription Factor ChIP-seq from ENCODE identiﬁed 161 factors in
this region and Chromatin State Segmentation by HMM demonstrated
the human intron is a regulatory region in nine cell lines. Histone
modiﬁcations by ChIP-seq from ENCODE showed areas of high signal
Fig. 1. The human GLI1 ﬁrst intron (outlined with blue dashed lines) has the genomic characteristics of an enhancer. Public data and our sequencing reveal six GLI
binding sites (GBS) with 8/9 consensus nt in regions of very high sequence conservation between mammalian species. Red boxes indicate the GBS; conservation peaks
with reference to the human sequence are shown; salmon indicates> 80% sequence identity in 100 nt windows, TSS is the 5′ end of the ﬁrst exon and the
translational start is the 5′ end of the second exon. Peaks of H3K27ac and DNase hypersensitivity clusters are shown. Additional analysis and transcription factor ChIP
seq plots are provided in Supplemental materials Fig. 1.
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from CTCF, H3Kme1 and H3K27ac in human stem cells (H1) and in
CML cells (K562) (Fig. 1, and Fig. 1 in Supplemental materials).
2.2. Epigenetic markers of gene activation and GLI2 binding are stimulated
in the mouse GLI1 second intron (equivalent to human ﬁrst intron) by SHH
signaling
In order to interrogate the occupancy of the region by activating
epigenetic histone marks and their response to SHH we utilized mouse
LIGHT2 (LT2) [36] cells because of their known, well-characterized
response to SHH in the presence of intact SHH/GLI1 signaling. The
mouse GLI1 sequence previously described by us includes an additional
exon relative to the human sequence with a short ﬁrst intron, making
the mouse second intron equivalent to the human ﬁrst intron [34]. SHH
activates GLI1 expression [35]. Indications that the intronic region is an
active regulatory region led us to look for evidence that SHH increases
transcriptional activation through the proximal promoter and intronic
region of GLI1 in human and mouse cells (Fig. 2).
LT2 [36] cells demonstrated stimulation of occupancy of the TSS
region and introns by BRD4, H3K27ac and H3K4me3 with recombinant
SHH. We then wished to determine if this SHH responsiveness was
dependent on GLI and to accomplish this we used GLI2/3 (-/-) mouse
embryonic ﬁbroblasts (MEF). BRD4, H3K27ac and H3K4me3 occupied
this region in the absence of GLI2 and GLI3, however, SHH stimulation
of occupancy was not seen in cells lacking GLI2 and GLI3 (Fig. 3).
The highest occupancy by BRD4, H3K27ac and H3K4me3 occur
around the TSS and the 5′ end of the mouse ﬁrst and second intron
(Figs. 2, 3). In order to establish if the SHH responsiveness could be
upstream of SMO we stimulated LT2 cells (that have intact SMO/GLI
signaling) with SMO agonist. H3K4me3 occupancy in the TSS region
and in the introns was increased with SMO agonist (SAG). Further, GLI2
occupancy was increased by SAG in the region of the TSS (Fig. 4).
Because inhibition of BRD4 binding by I-BET151 in mouse cells
reduced GLI1 expression and is a candidate cancer therapy [28] we
wished to determine the eﬀect of I-BET151 on BRD4 and activating
histone marks in human tumor cells with an intact SHH signal pathway
but SHH autonomy to avoid potentially confounding eﬀects of SHH.
Activated histone marks are present in the human ﬁrst intron and TSS
region along with BRD4 occupancy. BRD4 occupied the human GLI1
promoter and ﬁrst intron and could be driven oﬀ by the inhibitor I-
BET151 as shown in Fig. 5. As in mouse cells, I-BET151 signiﬁcantly
reduced GLI1 expression in human tumor cells (Fig. 2 in Supplemental
materials). However, the levels of H3K27ac and H3K4me3 occupancy
were not signiﬁcantly changed by I-BET151 treatment, suggesting that
occupancy is SHH dependent but not BRD4 dependent.
2.3. Putative GBS in human and mouse GLI1 5′ introns
In addition to the public data our sequencing previously identiﬁed
six highly conserved GLI putative binding sites (GBS, Fig. 1) with 8/9 nt
matching the consensus sequence (GACCACCCA). The GBS sequences
lined up with peaks of sequence conservation in this region (Fig. 1).
Starting with the human sequence as the reference there was greater
than 80% sequence identity between human, mouse, rat, dog and cow
in the region of ﬁve of the six GBS (GBS 1–5) and greater than 70%
sequence identity in the region of the sixth GBS between human, dog
and cow. Conservation did not extend beyond mammals (data not
shown). The structure of the mouse GLI1 gene diﬀers in that there is a
second untranslated exon [34] and the second intron shows four pu-
tative GBS with 8/9 nt matching the consensus sequence in the con-
served regions. When the conservation plot compared mouse to human
with the mouse sequence as the reference the GBS sequences line up
with peaks of maximum conservation (Fig. 3 in Supplemental mate-
rials). Importantly the precise GBS sequences in the mouse were the
Fig. 2. Epigenetic marks are present in the second intron of the mouse GLI1 locus upon SHH stimulation. BRD4, H3K27ac and H3K4me3 occupancy were analyzed by
ChIP-quantitative PCR in SHH responsive cells (mouse LT2) treated with 1 μg/μl recombinant SHH-N (C25II Substitution) for 24 h. The signals were normalized to a
control ChIP performed using rabbit IgG. Error bars represent the S.E. of three independent experiments. p values≤ 0.05 are considered statistically signiﬁcant and
indicated by an asterisk. (Below) a schematic of the mouse GLI1 locus from -6,000 nt to +3000 nt, relative to the transcription start sites (TSS) is shown. The probes
PS1-PS11 are represented as shaded boxes (sequences in Methods section). 5′ -> 3′ is left to right. The solid line represents introns, the dashed line represents
upstream sequence and the colored boxes represent exons. Green lines in the intron represent the locations of the mouse GBS.
R. Taylor, et al. DNA Repair 79 (2019) 10–21
12
same as those in the human including the mismatched nt. (Table 1 in
Supplemental materials).
2.4. GLI1 and GLI2 can bind consensus sequences found in the intron
We determined that both human GLI1 and GLI2 protein bind all six
of the conserved GBS by gel shift analysis (Fig. 6). Puriﬁed human GLI1
protein (aa 211-1106) or puriﬁed GLI2 (aa. 84-355) partial proteins
were incubated with the probes. Retarded bands were observed for all
six conserved sites (arrow, Fig. 6).
2.5. Human GLI1 intron promotes transcriptional regulation of expression
reporters by GLI1 and GLI2
We then determined whether the ﬁrst intron of the human GLI1
locus is competent to activate transcriptional activity through GLI1 or
GLI2 binding to the GBS by cloning the full sequence of the intron into
luciferase activity reporter vectors (Fig. 7A) utilizing HeLa human cells
because they have no base line GLI1 expression and have been used
extensively by us and others for plasmid based transduction allowing
facile introduction and analysis of GLI expression and deletion con-
structs. In the presence of both human GLI1 and human GLI2 expression
constructs, no activity above background was observed in either the
basic vector or a vector designed to mimic promoter activity
(pGL3:empty). However, in a vector designed to simulate enhancer
activity (pGL3:in1A), both hGLI1 and hGLI2 stimulated transcription of
the luciferase reporter gene (Fig. 7B, C). We deleted GBS individually to
determine their contribution to GLI activity in the luciferase system.
When hGLI1 was added we found that deletion of GBS1 (D1) or GBS4
(D4) (Fig. 7B) signiﬁcantly reduced transcriptional activity. When
hGLI2 was added GBS2 (D2) as well as GBS1 and GBS4 signiﬁcantly
reduced activity (Fig. 7C). We next deleted combinations of elements to
expose groups of elements that may act in combination to promote
transcriptional activity. When all GBS elements were deleted in a single
construct (D11), almost all transcriptional activity was lost. When sti-
mulated with hGLI1, we found that D8, which deleted GBS elements
4–6, but not D7, which deleted GBS elements 1–3, had signiﬁcantly
reduced activity indicating that GBS1 was less eﬀective than GBS4. In
contrast, when hGLI2 was added the reporter stimulation was sig-
niﬁcantly reduced in combination deletions D7 and D9 that removed
GBS1, GBS2 and GBS4. However, D8 and D10 did not alter expression
indicating that GBS4 was less eﬀective. Thus we conclude that hGLI1
primarily acted through GBS1 and GBS4 while hGLI2 primarily acted
through GBS1, GBS2 and GBS4.
2.6. Mass spectroscopy, proximity ligation assays and co-
immunoprecipitation identify histone variant H2A.Z as a GLI1 binding
partner
A GLI1-GFP construct was produced and activates transcription
(data not shown) following transfection into HeLa cells. Proteins were
isolated with GFP trap beads and separated on SDS PAGE gels and mass
spectrometric analysis performed. In two independent isolations his-
tone variant H2A.Z demonstrated high LFQ (label-free quantiﬁcation)
and high LFQ ratio between the GLI1-GFP and control plasmid pull
down (Supplemental materials Fig. 4). The analysis also identiﬁed GLI1
(since that was the pull down antibody), SuFu (known to bind GLI1),
and interestingly, SUV39H1, a histone methyltransferase considered to
be a histone editor [37].
The interaction between GLI1 and histone H2A.Z was conﬁrmed
with proximity ligation assays (PLA; Fig. 8) utilizing Rh30 because of
very high levels of GLI1 expression and protein levels, maximizing the
opportunity to see the protein-protein interaction with a favorable
signal to noise ratio. PLA is performed using primary antibodies from
diﬀerent species directed to the molecules of interest. The secondary
antibodies are labeled with a DNA bar code and this is then recognized
Fig. 3. Epigenetic marks are not responsive to SHH stimulation in cells that lack GLI2 and GLI3 (Gli2-/-;Gli3-/- MEFs). Brd4, H3K27ac and H3K4me3 occupancy in
the region were analyzed by ChIP-quantitative PCR in Gli2-/-;Gli3-/- MEFs treated with 1 μg/μl recombinant SHH-N (C25II Substitution) for 24 h. The signals were
normalized to a control ChIP performed using rabbit IgG. Error bars represent the S.E. of three independent experiments. p values≤ 0.05 are considered statistically
signiﬁcant and indicated by an asterisk. (Below) a schematic of the mouse GLI1 locus from -6,000 nt to +3000 nt, relative to the transcription start sites (TSS) is
shown. The probe sets (PS) PS1-PS11 are represented as shaded boxes (sequences in Methods section). 5′ - > 3′ is left to right. Green lines in the intron represent the
locations of the mouse GBS.
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by circle forming DNA oligos. When the proteins are closer than 40 nm
the oligos can be ligated and ampliﬁed by rolling circle ampliﬁcation.
The interaction is then visualized utilizing ﬂuorescently labeled oligos
that hybridize the circularized amplicon. This will result in hundreds
fold ampliﬁcation of signal and allows localization of the interaction.
This allows the identiﬁcation of protein-protein interactions without
overexpression or use of exogenous labeled proteins or plasmids, and
the method is highly sensitive and very speciﬁc. Cells were treated with
antibodies to GLI1 and to H2A.Z. Using confocal microscopy PLA signal
indicating binding of GLI1 and H2A.Z was observed in Rh30 cells
(human rhabdomyosarcoma with ampliﬁed GLI1) illustrated in Fig. 8A
and B. HeLa cells, which do not have detectable GLI1, did not display
PLA signal (Fig. 8C and D). Co-immunoprecipitation conﬁrmed the
interaction between GLI1 and H2A.Z (Fig. 9). GLI1 antibody, but not
normal rabbit IgG, pulled down H2A.Z identiﬁed with western blot
analysis.
Public ChIP seq data showed multiple peaks of H2A.Z reads in the
human GLI1 ﬁrst intron in trophoblast, hES cells, mesenchymal stem
cells derived from hES, neural progenitor cells derived from hES cells,
HeLa, A549, HepG2 cells and a variety of others (Fig. 5, Supplemental
materials). The H2A.Z read probability was maximal in the regions
containing at least four of the six human GBS sequences in the GLI1 ﬁrst
intron.
3. Discussion
Here we show that the ﬁrst intron of the human GLI1 gene is a
regulatory region. Further, the histones present in the mouse and
human GLI1 introns carry the active marks of H3K27ac and H3K4me3.
Both GLI2 occupancy of the regulatory region and active epigenetic
histone marks are SHH dependent. This SHH eﬀect requires GLI2 and/
or GLI3 as it is absent in GLI2/GLI3 null cells. The human ﬁrst intron
contained six conserved GBS in regions of high sequence conservation
that are capable of binding GLI1 and GLI2 in vitro. Deletion analysis
demonstrates that binding to some but not all of the GBS signiﬁcantly
aﬀects gene expression and that overall the elimination of all sites
greatly reduces gene reporter expression. We show that SHH drives
occupancy of GLI2, H3K27ac and H3K4me3 in this region and that the
human intron can regulate GLI1 expression. The intron contains ele-
ments capable of activation of GLI1 expression explaining in part GLI1
auto-regulation.
While the epigenetic landscape is consistent with a nucleosome free
region our work and the public data demonstrate the presence of his-
tones within the intron and indeed our results show binding of GLI1 to
H2A.Z, a developmentally relevant histone. The region is primed for
remodeling and the histone reader protein BRD4 is present. H3K27ac
and H3K4me3 occupancy is not signiﬁcantly changed by removing
BRD4 from the human intron and transcription start site (TSS) region
with the small inhibitory molecule I-BET151 despite the fact that I-
BET151 reduces GLI1 expression in both mouse [28] and human cells
(Fig. 2 in Supplemental materials)
Concepts of transcriptional regulation through promoters and en-
hancers are rapidly evolving and the notion of a highly conserved
cluster of GBS within the GLI genes themselves oﬀers a potential me-
chanism for self-regulation by a positive feedback (feed forward) loop
of the principal activating transcription factors in the pathway, GLI1
and GLI2. This region then is an ideal location to further study both
function and regulation of GLI1. Interruption of the feedback loop could
be exploited in novel cancer therapy. Additionally, the regulatory re-
gion has been shown in the public data to bind dozens of other tran-
scription factors. Interestingly GBS6 can be seen to line up in ChIP seq
with the largest number of transcription factors (Fig. 2, Supplemental
materials). Our data using cellular extracts rather than puriﬁed protein
(not shown) reveals that GBS6 does not bind GLI1 or GLI2 in some
cellular contexts although the puriﬁed proteins do bind that site.
Elimination of the GBS6 site does not aﬀect expression of the reporter
gene in the presence of GLI1 or GLI2. It is possible given the other
protein-protein interactions described here that the ability of that site to
bind GLI1 or GLI2 is impeded by occupancy of other transcription
factors.
Accumulating evidence suggests that transcriptional regulation oc-
curs in a landscape of protein complexes designed to not only create a
platform for transcriptional machinery but to facilitate the formation of
elongating RNA. This has led to the concept of transcriptional factories
[38]. The role of protein-protein interactions in the regions associated
with transcriptional regulation may be to facilitate movement of the
polymerase machinery through nucleosome organized DNA or alter-
natively the movement of DNA through the polymerase machinery.
While the concept of nucleosome free regions allowing the RNAPol II
complex to initiate may be overly simplistic, nucleosomes do present a
barrier to RNA elongation [39]. The presence of histone reader proteins
in the region of TSS may facilitate the polymerase activity through
nucleosomes that remain in a transcriptionally active area or in the
gene itself [40,41]. Bromodomain and extra terminal domain proteins
bind acetylated histone tails though the bromodomain, a highly con-
served 110 amino acid domain that forms alpha helices and breaks
through proximal promoter pausing. BRD4 in particular may have
histone chaperone activity that facilitates progression of RNAPII [42].
The presence of direct GLI1 and histone H2A.Z interaction is sur-
prising. H2A is one of the four core histone proteins and is known to
have several important variants. The H2A.Z variant is required for
embryonic development and its knock out is embryonic lethal.
Incorporation of H2A.Z into nucleosomes weakens the DNA winding
Fig. 4. GLI2 and H3K4me3 are enriched in the GLI1 locus with SMO agonist
(SAG) stimulation in LT2 SHH responsive mouse cells by ChIP-quantitative
PCR. The signals were normalized to a control ChIP performed using rabbit IgG.
Error bars represent the S.E. of three independent experiments. p values≤ 0.05
are considered statistically signiﬁcant and indicated by an asterisk. (Below) a
schematic of the mouse GLI1 locus from -6,000 nt to +3000 nt, relative to the
transcription start sites (TSS) is shown. The probe sets (PS) PS1-PS11 are re-
presented as shaded boxes (sequences in Methods section). 5′ - > 3′ is left to
right. Green lines in the intron represent the locations of the mouse GBS.
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and positioning of such nucleosomes around transcriptional start sites
aﬀects expression of the associated genes [43,44]. H2A.Z variant his-
tones are important in gene activation and silencing and are highly
conserved among species [45,46]. H2A.Z inﬂuences chromatin re-
modeling, occupies extended regions at developmental genes [47] and
is an oncogene when over-expressed, possibly as a result of enhancing
the expression of oncogenes like GLI1 [48–50]. Enrichment of H2A.Z is
thought to help decrease pausing [51] leading to active transcription
[52].
In humans, a signiﬁcant cancer burden is associated with mis-reg-
ulation of the Hedgehog/Patched/GLI (HH/PTCH/GLI) pathway
[1,53]. GLI1 gene targets sustain proliferation [10], inhibit apoptosis
[10], promote angiogenesis [54] and promote tumor cell migration
[55]. Wild-type p53 competes with GLI1 for the co-activator TAF9,
inhibiting GLI1’s oncogenic activity [56].
Transcription factors have proven to be diﬃcult therapeutic targets
because of speciﬁcity, selectivity and diﬀerential sensitivity [57].
Overcoming those concerns or generating new therapeutic approaches
for GLI1 will require a better understanding of the biochemical me-
chanisms that regulate GLI1 gene expression and function. While the
optimal GLI binding sequence is widespread in the genome it is im-
portant to realize that nt mismatches from the consensus are in many
Fig. 5. BRD4 occupancy is reduced with treatment by I-BET151 in the human GLI1 locus. Brd4, H3K27ac and H3K4me3 occupancy were analyzed by ChIP-
quantitative PCR in BL1648 (human Burkitt lymphoma cells not dependent on SHH signaling) cells treated with 1μM I-BET151 for 24 h. The signals were normalized
to a control ChIP performed using rabbit IgG. I-BET151 (an inhibitor of bromodomain end terminal protein) reduces BRD4 without changing active chromatin mark
occupancy in the ﬁrst intron of the human GLI1 locus. Error bars represent the S.E. of three independent experiments, unless otherwise indicated. p values≤ 0.05 are
considered statistically signiﬁcant and indicated by an asterisk. (Below) A schematic of the human GLI1 locus from -5,000 nt to +3700 nt, relative to the tran-
scription start site (TSS) is shown. The probe sets (PS) PS12-PS20 are represented as shaded boxes (sequences in Methods section). 5′ - > 3′ is left to right. Green lines
in the intron represent the locations of the human GBS.
Fig. 6. Gel shift assays demonstrate human GLI1 protein binds the putative GLI1 binding sites in the intronic region of human GLI1 gene. Labeled DNA probes were
29 mers including the 8/9 nt consensus sequence embedded, in the genomic sequence of the ﬁrst intron. Electrophoretic mobility shift assays using puriﬁed human
GLI1 or GLI2 protein demonstrate shifted bands (arrows) with speciﬁc oligonucleotide DNA probes (GBS1-6). The shifted bands are abrogated by> 100 fold molar
excess of non-radiolabeled oligonucleotide. Control protein or a non-speciﬁc oligonucleotide DNA at> 100 fold molar excess did not aﬀect the mobility shift,
indicating the speciﬁcity of GLI-intron interaction. The lanes for GBS1, 2, and 3 with GLI1 are from the same gel utilizing the control probe shown in the ﬁrst lane.
They were separated in the ﬁgure to align with the appropriate lanes for GLI2.
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cases important to the functional regulation of gene targets [58]. The
importance of the base pair diﬀerences from the consensus optimal
sequence in the GBS described here is underscored by their conserva-
tion from human to mouse suggesting that these diﬀerences are more
signiﬁcant than just a relaxed binding domain. The cluster of GBS in the
proximal intronic region of GLI1 is reminiscent of a similar structure in
the Drosophila patched gene where it is thought to be part of a ﬁne
tuning response system and is evolutionarily conserved [59].
Mechanisms of control of GLI1 expression are important because
GLI gene transcription is auto-regulated. Mouse GLI3 directly binds to
the GLI1 promoter and induces GLI1 transcription in response to SHH
[60]. Other experiments suggest that GLI1 is a direct target of GLI2
[61]. The results presented here imply that GLI1 can regulate the ex-
pression of GLI1 itself. Since non-canonical signaling may result in
oncogenic expression of GLI1, inhibiting upstream molecules like SMO
may not be useful for cancer therapy. Molecular inhibitors of GLI1 that
directly aﬀect its transcription by breaking the feed forward cycle may
be required for meaningful therapy. A deeper understanding of the
elements that regulate GLI1 expression will help achieve this goal.
4. Experimental procedures
4.1. Chromatin immunoprecipitation (ChIP)
10 million cells were cross-linked in 1% formaldehyde (Thermo
scientiﬁc) for 10–15min in room temperature and then blocked by 0.
125mM glycine (Ameresco) for 5min in room temperature. Cell pellets
were harvested and washed with pre-chilled PBS twice. Then 350 μl of
lysis buﬀer was added to lyse cells. Cell lysates were then sonicated
(Bioruptor™ UCD-200) to yield DNA fragments that have sizes between
300 and 800 base pairs. Thereafter, cell lysate were cleared after 10min
at 15,000 xg centrifugation. Supernatants were collected and diluted
with ChIP dilution buﬀer by 10 fold. Diluted lysates were then pre-
cleared by protein A/G beads (Invitrogen) that had been blocked by
BSA (Sigma) and salmon sperm DNA (Trevigen). Pre-cleared lysates
were then aliquoted and incubated with 4 μg ChIP antibodies for 1 h.
Then pre-blocked A/G beads were added for overnight incubation. On
the second day, the beads were spun down and washed with low salt
wash buﬀer, high salt wash buﬀer and lithium chloride buﬀer se-
quentially. Elution buﬀer was then added to elute protein-DNA com-
plexes from the beads. Then the eluates were subjected to reverse cross-
linking, RNA digestion (RNAse A: Sigma) and protein digestion
(Proteinase K, Invitrogen) sequentially. A DNA puriﬁcation kit
(QIAGEN) was employed to purify DNA from previous steps. Puriﬁed
DNAs were then utilized for q-PCR to quantify the abundance of asso-
ciated proteins in speciﬁc regions of the gene locus.
4.2. Antibodies
BRD4 (Bethyl lab, Cat # A301-985A50), Rabbit IgG (Abcam, Cat #
46540), H3K27ac (Abcam, Cat # ab4729) and H3K4me3 (Abcam, Cat #
ab1012), GLI2 (R&D, Cat # AF3526), Myc (Covance, Cat # MMS-
150 P).
4.3. Cell lines
LIGHT2 (LT2) cells [62], Gli2−/− Gli3-/- MEFs [63], BL1648 cells
[14] were used in these experiments.
Fig. 7. The hGLI1 intron acts as a transcriptional enhancer when
stimulated by GLI transcription factors. A. Diagram showing 6 GLI
binding sites (GBS, red boxes). A series of deletion mutants was
generated by mutagenic inverse PCR to remove the bracketed
sequences. D (for deletion) 1–10 remove the GBS individually and
in combinations. D11 (not shown) removes the entire intron. B
and C. Luciferase reporter assays demonstrate the ability of hGLI1
(B) and hGLI2 (C) to stimulate transcription with enhancer-like
activity following transfection into HeLa cells. Luciferase signal is
displayed as fold change upon addition of GLI transcription factor
(open bars) over no transcription factor (closed bars). Error bars
represent the S.E. of three independent experiments. Statistical
signiﬁcance (* = p < 0.05) between full length (FL) and deletion
constructs is indicated. TF= transcription factor.
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4.4. Buﬀers
ChIP lysis buﬀer (1% SDS, 10mM EDTA, 50mM Tris, pH 8.0), ChIP
dilution buﬀer (0.01% SDS, 1.2 mM EDTA, 16.7 mM Tris, 167mM
NaCl, 1% Triton X-100), low salt wash buﬀer (0.1% SDS, 1% Triton X-
100, 2mM EDTA, 150mM NaCl, 20mM Tris, pH 8.0), high salt wash
buﬀer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 500mM NaCl, 20mM
Tris, pH 8.0), Lithium chloride buﬀer (0.25M LiCl, 1% NP40, 1%
deoxycholic acid, 1 mM EDTA, 10mM Tris pH 8.0), elution buﬀer (1%
SDS, 100mM NaHCO3).
4.5. Primers
Mouse GLI1 locus:
Fig. 8. GLI1 binds H2A.Z. Confocal microscopy images of PLA and co-IP. a and b are Rh30 human rhabdomyosarcoma cells with high levels of GLI1, c and d are HeLa
cells that lack GLI1, e and f are no primary antibody controls with Rh30 cells. Blue is DAPI nuclear stain, red is PLA signal, and white is processed brightﬁeld data to
allow visualization of approximate cell boundaries. PLA signal over the nuclei is present in a and b, but not in the controls c-f. Additional controls where only one of
the primary antibodies is present likewise did not have PLA signal.
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PS1 Forward primer: GAGCAGACACCATGACCAAA
Reverse primer: TTGGTTGGCCCAGGTAGTAG
PS2 Forward primer: TCCAGAATTGGAAGGCTCAC
Reverse primer: GCCCAAGGATCTAGCAGTTG
PS3 Forward primer: AAGACCCCAAAGGCTCATCT
Reverse primer: GTGGCAGCTCATCACAGAAA
PS4 Forward primer: ATTCCCAGCAACCACATGAT
Reverse primer: GAGGGCATCAGATCCCATTA
PS5 Forward primer: TAAGTTCGCCAGTGCAATCA
Reverse primer: AGTTGGGGTTTGGGAGAAAG
PS6 Forward primer: AGGAGATGCTCTGACGCCTA
Reverse primer: AGTTCCCTCTACCACGCAGA
PS7 Forward primer: AGGAGATGCTCTGACGCCTA
Reverse primer: TGCAGAGAAAAGAAGGCACA
PS8 Forward primer: AGCTGGGGAGACCTTGTTTT
Reverse primer: GGCCTCTACGGAGTTTCCTT
PS9 Forward primer: ACCCAGGAATCCAAGGTGTC
Reverse primer: TCCTGAAAGCAGGCAGTAGC
PS10 Forward primer: CGCTGAGAGAGGGAAGAATG
Reverse primer: AAAGGTTTTCTGGGCTGGAT
PS11 Forward primer: GATTTCCCCCAAAACCAAAC
Reverse primer: GTGGAACACACGGAAGGTCT
Human GLI1 locus:
PS12 Forward primer: ACTACAGCCAGGGAGTGTGG
Reverse primer: TGTGTCCTCTGCAACCAGTC
PS13 Forward primer: CAATGTGGTCAAGACGGATG
Reverse primer: TCCCATAGGGGTCAAGTGAG
PS14 Forward primer: GGGGAGGAGGAAGCAGATAG
Reverse primer: CTGGGAAAAACCAGGGAACT
PS15 Forward primer: AACCCACTGACCTTCCACAC
Reverse primer: TTAGATTTGCATTGCCATCG
PS16 Forward primer: CTAGGGAAAGGGGCTTCAGT
Reverse primer: CACCCTTTGGATGGAACTTG
PS17 Forward primer: GGTAACCCCAGGTGTGTGTC
Reverse primer: TCCCCTAAAGCACAAGCATC
PS18 Forward primer: CGGCTGCTATAACCAGCAAC
Reverse primer: CTCCTCCTCTCAGCACATCC
PS19 Forward primer: ACAGCAGCACCTTCTTCCTC
Reverse primer: GGTTCCTGAGGGGAGTCTTC
PS20 Forward primer: CTCTGCCTCTCTGGGACATC
Reverse primer: GGTGCCTGTAATCCCAGCTA
4.6. Deletion mutations
4.6.1. Luciferase transcriptional activity assay
Full-length human GLI1 intron (chr12:57,460,202-57,463,664;
assembly hg38 from Dec. 2013) was cloned from HeLa cell lysate and
ligated into pGL3 luciferase expression vectors using Gibson Assembly
(NEB). Potential GLI binding sites (8/9 consensus bases) were identiﬁed
using MacVector and deleted individually or in groups via inverse PCR.
For luciferase assays, plasmids were cotransfected into HeLa cell culture
using HilyMax (Dojindo) reagent. 30 h post transfection, cells were
lysed and relative luciferase and renilla signal was detected using the
Dual-Luciferase Reporter Assay system (Promega) with a Lumat lu-
minometer (Berthold). After subtracting baseline noise and normalizing
signal against renilla activity, statistical signiﬁcance was determined by
ANOVA (R).
Deletion primers:
Target
hGLI1 intron1 Forward Primer: GCCTGGGGTGAGACATTAGA
Reverse Primer: CGCCTGTAATTCCAACGCTT
D1 Forward Primer: TCTGAATCCTCTTTCAGGT
Reverse Primer: AGGAGGGGCCTCGATCCCC
D2 Forward Primer: AAGGCGGGACCGGGAGTAG
Reverse Primer: ACTGGCTGCAGACGGCTCC
D3 Forward Primer: TGTAGCCCCATTTCCTTGG
Reverse Primer: AGGCTAGTAAAAGGAAAATG
D4 Forward Primer: TCCGCACCTCGGTTGGAAAAG
Reverse Primer: GACCTTGGAACTAATGTTG
D5 Forward Primer: CCGGCCCGCTCCCGGTGG
Reverse Primer: TGGGATTTAGGGTGAGGGC
D6 Forward Primer: ACCCAGGCAAAGCTCCCAC
Reverse Primer: TGTTTTGGACTAATTGTGC
D7 Forward Primer: TGTAGCCCCATTTCCTTGG
Reverse Primer: AGGAGGGGCCTCGATCCCC
D8 Forward Primer: ACCCAGGCAAAGCTCCCAC
Reverse Primer: GACCTTGGAACTAATGTTG
D9 Forward Primer: CCGGCCCGCTCCCGGTGG
Reverse Primer: ACTGGCTGCAGACGGCTCC
D10 Forward Primer: CCGGCCCGCTCCCGGTGG
Reverse Primer: GACCTTGGAACTAATGTTG
D11 Forward Primer: ACCCAGGCAAAGCTCCCAC
Reverse Primer: AGGAGGGGCCTCGATCCCC
4.7. Electrophoretic mobility shift assays (EMSA)
EMSA was performed using DIG gel shift kit (Roche, Mannheim,
Germany) or with 32P labeled probe and the GLI1 protein preparation
was described previously [64]. Preparation of GLI2 Protein: 6xHisTag
GLI2 protein was produced in Escherichia coli using the pETBlue-2 blunt
cloning kit (Novagen, Madison, WI). The GLI2 aa 84–355 cDNA was
prepared by PCR (sense primer:5′- GGAGCAGCTGGCTGACCTCAAG
GAA-3′ and antisense 5′- CATCTCCACGCCACTGTCATTGTTG-3′) and
cloned into the EcoRV site of the pETBlue-2 plasmid DNA (Novagen).
For protein production, pETBlue-2 GLI2 construct was introduced into
the Tuner (DE3)pLacI competent cells (Novagen) and GLI2 protein was
induced with 1–2mM isopropyl-1-thio-1-D-galactopyranoside (IPTG)
for 3–4 h at 37OC. Bacteria were then harvested, sonicated, and cleared
by centrifugation. The 6xHisTag GLI2 aa 84–355 in the clear lysate was
puriﬁed using His-Spin Protein Miniprep kit with (Zymo Research, Ir-
vine, CA) with modiﬁcations. EMSA was performed using DIG gel shift
kit. 1 μl of GLI2 or control protein was used and the rest of the method
is the same with GLI1 procedure.
5 μl of GLI1 protein (aa 211-1106) or control protein (pinpoint
protein) was mixed with 2 μl of 5X binding buﬀer (Roche), H2O, and 0
or 1 μl (20 pmol) of unlabeled competitor oligonucleotides. The mixture
was incubated at 4O C for 10min. 1 μl (155 fmol) of double stranded
digoxigenin-labeled probe was added and the mixture was incubated at
4OC for 20min. Probes were designed using MacVector software
(MacVector, Inc., Cary, NC). Probe sequences are shown, listing the
sense sequence (5′→3′) followed by the antisense sequence (5′→3′)
used to produce the double-stranded probe. We used the following
probes (GBS sequences are in the Supplemental materials Table 1). GBS
Fig. 9. Co-immunoprecipitation (CO-IP) assay to detect the interaction between
GLI1 and H2A.Z in Rh30 cells. GLI1 or control antibody (normal rabbit IgG)
were used for CO-IP and H2A.Z was visualized following Western Blotting with
anti-H2A.Z antibody. A. Heavy chain IgG bands show that the equivalent
amount of each antibody was used. B. H2A.Z band is present in CO-IP lane with
GLI1 antibody.
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#1; sense 5′- CTCTGGCTCAGACCACCCTGCCTGCCCTT -3′ and anti-
sense 5′- AAGGGCAGGCAGGGTGGTCTGAGCCAGAG -3′
GBS #2; sense 5′- GGCGGCGACTTGGGTGGGCCGAGGAGGCA -3′
and antisense 5′- TGCCTCCTCGGCCCACCCAAGTCGCCGCC -3′
GBS #3; sense 5′- AGGGGAGATATGGGTGGGCTGTGGAACGC -3′
and antisense 5′- GCGTTCCACAGCCCACCCATATCTCCCCT -3′
GBS #4; sense 5′- AGCATCCCGGGATCACCCACCGCGCCGGC -3′
and antisense 5′- GCCGGCGCGGTGGGTGATCCCGGGATGCT -3′
GBS #5; sense 5′- AAGGTCGAGTTGGGAGGTCTTGGATGCGG -3′
and antisense
5′−CCGCATCCAAGACCTCCCAACTCGACCTT -3′
GBS #6; sense 5′- TCTACACACAGACCACACAGGCAAAGCTC -3′
and antisense 5′- GAGCTTTGCCTGTGTGGTCTGTGTGTAGA -3′
non-speciﬁc competitor; sense 5′- GAGGTAACCCAGGGCTTGTGTC
TGCG -3′ and antisense 5′- CGCAGACACACACCTGGGGTTACCTC -3′.
The GLI1- DNA complexes were separated by 5% TBE gel electro-
phoresis, transferred onto Zeta-Probe GT membranes (Bio-Rad), and the
shifted bands were visualized by anti-digoxigenin antibody and che-
miluminescence reagent (Roche, Mannheim, Germany).
4.8. Mass spectrometric analysis
4.8.1. GFP-GLI1 interaction screen
Adherent HeLa cells were transiently transfected with a plasmid
encoding either GFP-GLI1 fusion protein or GFP alone under con-
stitutive control of the CMV promoter. Expression of recombinant
protein was conﬁrmed visually via ﬂuorescent microscopy and by
western blotting. The fusion protein was shown to be functional with a
luciferase GBS reporter (data not shown). Cultures were expanded to
approximately 3.5× 107 cells and harvested via trypsinization. Cell
pellets were then lysed with modiﬁed RIPA buﬀer (50mM Tris-HCl pH
7.5, 400mM NaCl, 1 mM EDTA, 1% NP-40) and cleared by cen-
trifugation. Lysates were then incubated with pre-cleared, equilibrated
GFP-Trap beads (Chromotek) overnight at 4 °C. Next, beads were col-
lected by centrifugation and washed with modiﬁed RIPA buﬀer (50mM
Tris-HCl pH 7.5, 150mM NaCl, 0.1% NP-40, 1mM EDTA). Beads were
then heated to 70 °C for 5min in SDS loading buﬀer to elute proteins
from beads. The supernatant was then collected by centrifugation and
size-separated by SDS-PAGE. After gel ﬁxation, lanes were divided by
size and subjected to mass spec.
4.8.2. Mass spectrometry
All mass spectrometric experiments were performed on a nanoscale
UHPLC system connected to an Orbitrap Q-Exactive HF equipped with a
nanoelectrospray source (all Thermo Fisher Scientiﬁc, Bremen,
Germany). Each peptide fraction was auto-sampled and separated on a
15 cm analytical column (75 μm inner diameter) in-house packed with
1.9-μm C18 beads (Reprosil Pur-AQ, Dr. Maisch, Germany) using a 1 h
gradient ranging from 5% to 40% acetonitrile in 0.5% formic acid at a
ﬂow rate of 250 nl/min. The eﬄuent from the UHPLC was directly
electrosprayed into the mass spectrometer. The Q Exactive HF mass
spectrometer was operated in data-dependent acquisition mode and all
samples were analyzed using the previously described ‘fast’ acquisition
method [65]. All raw data analysis was performed with MaxQuant
software suite [66] version 1.5.0.0 supported by the Andromeda search
engine [67]. Data was searched against a concatenated target/decoy
(forward and reversed) version [68] of the UniProt Human fasta data-
base (downloaded from www.uniprot.org on 2014-01-23). Mass toler-
ance for searches was set to maximum 4.5 ppm for peptide masses and
20 ppm for HCD fragment ion masses. Data was searched with carba-
midomethylation as a ﬁxed modiﬁcation. A maximum of three mis-
cleavages was allowed while requiring strict trypsin speciﬁcity [69],
and only peptides with a minimum sequence length of seven were
considered for further data analysis. Peptide assignments were statis-
tically evaluated in a Bayesian model on the basis of sequence length
and Andromeda score. Only peptides and proteins with a false discovery
rate (FDR) of less than 1% were accepted, estimated on the basis of the
number of accepted reverse hits, and FDR values were ﬁnally estimated
separately for modiﬁed and unmodiﬁed peptides [70]. Protein se-
quences of common contaminants such as human keratins and pro-
teases used were added to the database. For LFQ quantiﬁcation a
minimum of two ratio-counts was required.
4.9. Proximity ligation assay (PLA)
PLA was performed as described by the manufacturer (Sigma-
Aldrich, St. Louis, MO). Rh30 cells (gift from Dr. Peter Houghton,
Greehey Children's Cancer Research Institute, San Antonio, TX), and
HeLa cells (ATCC, Manassas, VA) were interrogated with anti-GLI1
antibody (R&D Systems, Minneapolis, MN) and/or anti-H2A.Z antibody
(Cell Signaling, Danvers, MA) for PLA.
PLA labeled cells were imaged on a confocal microscope (Zeiss 510
META, Carl Zeiss, Jena, Germany). Z-stacks were acquired to allow for
three-dimensional rendering in Volocity software (Perkin Elmer,
Waltham, MA). DAPI ﬂuorescence images were processed in the
EBImage package or the R statistical programming environment to
better deﬁne the nuclear boundary. Diﬀerential Interference Contrast
data from brightﬁeld images were processed in Photoshop (Adobe, San
Jose, CA) using high pass ﬁltering and median ﬁltering to allow for
rough visualization of cell boundaries. No processing was done to PLA
ﬂuorescence. All images were handled equivalently in Volocity, they
were rendered in “3D Opacity” mode and channel opacity, density and
black levels were all set to the same between images. Each square in the
grid is approximately 22 μm on a side.
4.10. Co-immunoprecipitation assay
The following procedures were carried out at 4OC. Approximately
2×10 7 Rh30 cells were resuspended and incubated in 1ml of cell lysis
buﬀer (Cell Signaling Technology) for 30min with gentle rocking. The
lysate was then homogenized by passing through a 26 G needle for
several times and cleared by centrifugation for 10min. at 10,000 rpm.
The clear lysate was incubated with 20 μl of Anti-GLI1 antibody
(Rockland) or control antibody (Cell Signaling Technology) for 30min
and then was incubated with 20 μl of protein A/G-magnetic beads
(Thermo Scientiﬁc) for 30min with gentle rocking. GLI1-H2A.Z
Immune complex was collected by using a magnetic rack for 1min,
washed with lysis buﬀer, and then eluted with low pH IgG elution
buﬀer (Thermo Scientiﬁc). The eluate was then neutralized with an
equal volume of 1M Tris.Cl (pH 7.6). All the following procedures were
carried out at room temperature. The GLI1-H2A.Z eluate was separated
on a SDS-PAGE gel, transferred onto a nitrocellulose membrane and
incubated in PBST buﬀer with 5% milk for 30min. The membrane was
washed with PBST buﬀer, incubated with polyclonal rabbit H2A.Z an-
tibody (Active Motif) (1:4000 dilution) in PBST buﬀer with 5% milk for
1 h. The membranes were washed with PBST buﬀer (1X PBS, 0.3%
Tween-20) and incubated with secondary antibody conjugated with
HRP (Donkey anti Rabbit IgG-HRP, Santa Cruz Biotech) for 1 h (1:8000
dilution in PBST with 5% milk). The membrane was then washed 3
times with PBST buﬀer. The H2A.Z protein was visualized using
SuperSignal West Pico chemiluminescence kit (Thermo Scientiﬁc).
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